Biond Biologics Ltd., a private clinical-stage biopharmaceutical company, has entered a clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt, Germany, to evaluate its immunotherapy agent BND-35 in combination with Merck KGaA’s anti-EGFR monoclonal antibody cetuximab (Erbitux) in a Phase 1 clinical trial (BND-35-001, NCT06274437) for the treatment of patients with unresectable or metastatic solid tumors.   Under the agreement, Merck KGaA will supply Biond Biologics...